J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

Kymera Therapeutics (KYMR) stock surged as the company outlined its 2025 outlook at the J.P. Morgan Healthcare Conference. Read more here.

On Tuesday, Kymera Therapeutics shares leaped 12% following the biotechnology firm's update on its product pipeline. The New York-based company announced progress in its programs for atopic dermatitis ...

NDAQ:KYMR) Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral ...

A statement from Gilead indicates that the deal is likely to lower its 2025 GAAP and non-GAAP earnings per share by $0.15 to ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...

Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic ...

Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...

Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...